GAITHERSBURG, Md., May 11, 2020 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, to issued two letters to stockholders from new OpGen CEO Oliver Schacht and Chairman of the Board William Rhodes.
Both letters can be found in full below:
Dear Stockholders,
As the newly appointed president and CEO of OpGen I want to take a moment to formally introduce myself
and share the vision our new management team has for the company with regards to our business outlook, product pipeline and growth strategy for this year and beyond.
This is an exciting time for OpGen, and I very much look forward to
working with the entire team through the next phase of its growth.
Market Data 
Markets 
AI
